{
    "hands_on_practices": [
        {
            "introduction": "To understand how nitrogen-containing bisphosphonates function, we must first look at their molecular target. These drugs work by disrupting a critical metabolic pathway within osteoclasts, the cells responsible for bone breakdown. This practice will guide you through the application of Michaelis-Menten kinetics to quantify the inhibitory effect of a bisphosphonate on its target enzyme, Farnesyl Pyrophosphate Synthase (FPPS), providing a foundational understanding of the drug's mechanism of action. ",
            "id": "4945701",
            "problem": "A nitrogen-containing bisphosphonate inhibits Farnesyl Pyrophosphate Synthase (FPPS), the mevalonate-pathway enzyme that condenses isopentenyl pyrophosphate (IPP) with dimethylallyl pyrophosphate to produce longer-chain isoprenoids required for protein prenylation. Assume classical steady-state Michaelis–Menten kinetics with competitive inhibition by the bisphosphonate at the IPP binding site. You measure the initial velocity of FPPS at a fixed IPP concentration with and without inhibitor under identical conditions.\n\nGiven the following experimentally determined parameters for the IPP substrate and the inhibitor:\n- Michaelis constant for IPP: $K_{m} = 2\\,\\mu\\mathrm{M}$.\n- Inhibitor dissociation constant (competitive): $K_{i} = 5\\,\\mathrm{nM}$.\n- IPP concentration during the assay: $\\left[\\mathrm{IPP}\\right] = 10\\,\\mu\\mathrm{M}$.\n- Inhibitor concentration during the assay: $\\left[\\mathrm{I}\\right] = 50\\,\\mathrm{nM}$.\n\nUsing the competitive inhibition framework, compute the ratio of the inhibited to uninhibited initial velocities, $v_{i}/v_{0}$, at the stated concentrations. Then, based on the principle that prenylation flux is approximately proportional to FPPS flux under substrate-saturating downstream conditions, interpret the relative prenylation deficit that would follow from the computed velocity ratio.\n\nReport only the numerical value of $v_{i}/v_{0}$ as a dimensionless decimal. Round your answer to three significant figures.",
            "solution": "The problem requires the calculation of the ratio of inhibited to uninhibited initial reaction velocities, $v_{i}/v_{0}$, for an enzyme-catalyzed reaction under competitive inhibition. All necessary parameters are provided, and the problem is scientifically well-grounded in the principles of enzyme kinetics.\n\nThe initial velocity of an enzymatic reaction, $v_{0}$, following Michaelis–Menten kinetics in the absence of an inhibitor is given by the equation:\n$$v_{0} = \\frac{V_{\\max} [\\mathrm{S}]}{K_{m} + [\\mathrm{S}]}$$\nwhere $V_{\\max}$ is the maximum reaction velocity, $[\\mathrm{S}]$ is the substrate concentration, and $K_{m}$ is the Michaelis constant for the substrate. In this problem, the substrate $[\\mathrm{S}]$ is isopentenyl pyrophosphate, $[\\mathrm{IPP}]$.\n\nFor competitive inhibition, the inhibitor, $[\\mathrm{I}]$, binds reversibly to the enzyme's active site, competing with the substrate. This type of inhibition increases the apparent Michaelis constant, $K_{m}^{\\mathrm{app}}$, but does not affect the maximum velocity, $V_{\\max}$. The apparent Michaelis constant is given by:\n$$K_{m}^{\\mathrm{app}} = K_{m} \\left(1 + \\frac{[\\mathrm{I}]}{K_{i}}\\right)$$\nwhere $K_{i}$ is the dissociation constant of the enzyme-inhibitor complex. The factor $\\left(1 + \\frac{[\\mathrm{I}]}{K_{i}}\\right)$ is often denoted by the symbol $\\alpha$.\n\nThe initial velocity in the presence of a competitive inhibitor, $v_{i}$, is therefore:\n$$v_{i} = \\frac{V_{\\max} [\\mathrm{S}]}{K_{m}^{\\mathrm{app}} + [\\mathrm{S}]} = \\frac{V_{\\max} [\\mathrm{S}]}{K_{m} \\left(1 + \\frac{[\\mathrm{I}]}{K_{i}}\\right) + [\\mathrm{S}]}$$\n\nTo find the ratio $v_{i}/v_{0}$, we divide the equation for the inhibited velocity by the equation for the uninhibited velocity:\n$$\\frac{v_{i}}{v_{0}} = \\frac{\\frac{V_{\\max} [\\mathrm{S}]}{K_{m} \\left(1 + \\frac{[\\mathrm{I}]}{K_{i}}\\right) + [\\mathrm{S}]}}{\\frac{V_{\\max} [\\mathrm{S}]}{K_{m} + [\\mathrm{S}]}}$$\nThe terms $V_{\\max}$ and $[\\mathrm{S}]$ in the numerators cancel, yielding the simplified expression:\n$$\\frac{v_{i}}{v_{0}} = \\frac{K_{m} + [\\mathrm{S}]}{K_{m} \\left(1 + \\frac{[\\mathrm{I}]}{K_{i}}\\right) + [\\mathrm{S}]}$$\n\nThe given parameters are:\n- $K_{m} = 2\\,\\mu\\mathrm{M}$\n- $K_{i} = 5\\,\\mathrm{nM}$\n- $[\\mathrm{S}] = [\\mathrm{IPP}] = 10\\,\\mu\\mathrm{M}$\n- $[\\mathrm{I}] = 50\\,\\mathrm{nM}$\n\nBefore substituting these values, we must ensure consistent units. The term $\\frac{[\\mathrm{I}]}{K_{i}}$ is a dimensionless ratio, so we can use the provided units directly for that calculation:\n$$\\frac{[\\mathrm{I}]}{K_{i}} = \\frac{50\\,\\mathrm{nM}}{5\\,\\mathrm{nM}} = 10$$\nThe factor $\\alpha$ is therefore:\n$$\\alpha = 1 + \\frac{[\\mathrm{I}]}{K_{i}} = 1 + 10 = 11$$\n\nNow, we can substitute the values of $K_{m}$, $[\\mathrm{S}]$, and $\\alpha$ into the expression for the velocity ratio. The concentrations of $K_m$ and $[\\mathrm{S}]$ are both in $\\mu\\mathrm{M}$, so their units are consistent.\n$$\\frac{v_{i}}{v_{0}} = \\frac{K_{m} + [\\mathrm{S}]}{K_{m} \\cdot \\alpha + [\\mathrm{S}]} = \\frac{2\\,\\mu\\mathrm{M} + 10\\,\\mu\\mathrm{M}}{(2\\,\\mu\\mathrm{M})(11) + 10\\,\\mu\\mathrm{M}}$$\n$$\\frac{v_{i}}{v_{0}} = \\frac{12\\,\\mu\\mathrm{M}}{22\\,\\mu\\mathrm{M} + 10\\,\\mu\\mathrm{M}} = \\frac{12\\,\\mu\\mathrm{M}}{32\\,\\mu\\mathrm{M}}$$\nThe units cancel out, resulting in a dimensionless ratio:\n$$\\frac{v_{i}}{v_{0}} = \\frac{12}{32} = \\frac{3}{8} = 0.375$$\nThe calculated ratio, rounded to three significant figures as requested, is $0.375$.\n\nThe problem also asks for an interpretation of this result. The ratio $v_{i}/v_{0} = 0.375$ indicates that the FPPS enzyme activity is reduced to $37.5\\%$ of its uninhibited level under the specified assay conditions. Since the problem states that prenylation flux is approximately proportional to FPPS flux, this implies that the rate of protein prenylation would also be reduced to approximately $37.5\\%$ of its normal rate. The relative prenylation deficit is the fractional decrease in flux, which is $1 - 0.375 = 0.625$, corresponding to a $62.5\\%$ reduction in this critical post-translational modification process. This deficit ultimately underlies the therapeutic effect of nitrogen-containing bisphosphonates in bone diseases, as it leads to osteoclast apoptosis. The final answer required is only the numerical value of the ratio.",
            "answer": "$$\\boxed{0.375}$$"
        },
        {
            "introduction": "A drug's potency at its molecular target is only part of the story; it must also successfully navigate the body to reach that target. This is a significant challenge for oral bisphosphonates, which are notoriously difficult for the body to absorb. This exercise demonstrates the fundamental pharmacokinetic principles of bioavailability and disposition, allowing you to calculate how much of a standard oral dose of alendronate actually enters the bloodstream and where it goes from there. ",
            "id": "4945659",
            "problem": "A patient is administered a single oral weekly dose of alendronate for osteoporosis prevention. Under strictly fasting conditions and with correct administration technique, the absolute bioavailability is experimentally measured as $0.7\\%$ (that is, $F = 0.007$ as a fraction). Let the administered oral dose be $D = 70$ mg. After entering the systemic circulation, the absorbed alendronate distributes such that a fixed fraction binds to bone hydroxyapatite and is retained, while the remainder is eliminated unchanged by the kidneys. Assume, based on population pharmacokinetic data, that $60\\%$ of the absorbed amount partitions to bone and $40\\%$ is renally excreted.\n\nUsing only the core definitions that (i) absolute bioavailability $F$ is the fraction of an oral dose that reaches the systemic circulation unchanged, and (ii) mass balance requires that the absorbed amount must equal the sum of the amounts retained in bone and eliminated by the kidneys, determine the following three quantities:\n- the absorbed dose,\n- the amount retained in bone,\n- the amount renally excreted,\n\nall for this single dose. Express each amount in milligrams (mg) and round your answers to two significant figures. Report your three results in the order listed above.",
            "solution": "The user-provided problem is first subjected to a rigorous validation process.\n\n### Step 1: Extract Givens\n- A single oral weekly dose of alendronate is administered.\n- Absolute bioavailability, $F$, is $0.7\\%$, which is given as a fraction $F = 0.007$.\n- Administered oral dose, $D$, is $70$ mg.\n- The fraction of the absorbed amount that partitions to bone is $60\\%$.\n- The fraction of the absorbed amount that is renally excreted is $40\\%$.\n- Definition of absolute bioavailability $F$: the fraction of an oral dose that reaches the systemic circulation unchanged.\n- Principle of mass balance: the absorbed amount must equal the sum of the amounts retained in bone and eliminated by the kidneys.\n- The quantities to be determined are: the absorbed dose, the amount retained in bone, and the amount renally excreted.\n- The final answers must be expressed in milligrams (mg).\n- The final answers must be rounded to two significant figures.\n- The results must be reported in the specified order: (1) absorbed dose, (2) amount retained in bone, (3) amount renally excreted.\n\n### Step 2: Validate Using Extracted Givens\n- **Scientifically Grounded**: The problem is grounded in the fundamental principles of pharmacokinetics. The drug, alendronate, is a well-known bisphosphonate used for osteoporosis. The given dose ($70$ mg weekly) is standard. The bioavailability ($F < 1\\%$) is characteristically low for oral bisphosphonates, and the stated value of $0.7\\%$ is scientifically realistic. The disposition of the drug—partitioning between bone uptake and renal excretion—is the correct physiological pathway for this class of compounds. The percentages provided for partitioning are also consistent with published pharmacokinetic data. The principles of bioavailability and mass balance are core tenets of the discipline. The problem is factually and scientifically sound.\n- **Well-Posed**: The problem is clearly stated and provides all necessary information to calculate the required quantities. The definitions are explicit, the numerical values are provided, and the objectives are unambiguous. A unique solution exists and can be determined through direct calculation.\n- **Objective**: The problem is expressed in precise, objective, and quantitative language. It is free from subjective claims or ambiguity.\n\n### Step 3: Verdict and Action\nThe problem is deemed **valid** as it is scientifically grounded, well-posed, and objective. A solution will be derived.\n\n### Solution Derivation\nLet $D_{oral}$ be the administered oral dose, $F$ be the absolute bioavailability, and $D_{abs}$ be the total amount of drug absorbed into the systemic circulation.\n\nThe problem provides the definition of bioavailability, which can be expressed mathematically as:\n$$D_{abs} = F \\times D_{oral}$$\nGiven the values $D_{oral} = 70$ mg and $F = 0.007$, the absorbed dose is:\n$$D_{abs} = 0.007 \\times 70 \\text{ mg} = 0.49 \\text{ mg}$$\n\nNext, we must determine the disposition of this absorbed amount. Let $M_{bone}$ be the amount of drug retained in bone and $M_{renal}$ be the amount eliminated by the kidneys. Let $f_{bone}$ be the fraction of the absorbed dose that partitions to bone, and $f_{renal}$ be the fraction that is renally excreted.\nThe problem states:\n- $f_{bone} = 60\\% = 0.60$\n- $f_{renal} = 40\\% = 0.40$\n\nThe amount retained in bone, $M_{bone}$, is calculated as:\n$$M_{bone} = f_{bone} \\times D_{abs}$$\nSubstituting the value of $D_{abs}$:\n$$M_{bone} = 0.60 \\times 0.49 \\text{ mg} = 0.294 \\text{ mg}$$\n\nThe amount renally excreted, $M_{renal}$, is calculated as:\n$$M_{renal} = f_{renal} \\times D_{abs}$$\nSubstituting the value of $D_{abs}$:\n$$M_{renal} = 0.40 \\times 0.49 \\text{ mg} = 0.196 \\text{ mg}$$\n\nAs a check for consistency, the principle of mass balance requires that the sum of the partitioned amounts equals the total absorbed dose:\n$$M_{bone} + M_{renal} = 0.294 \\text{ mg} + 0.196 \\text{ mg} = 0.49 \\text{ mg}$$\nThis sum is equal to the calculated $D_{abs}$, confirming the conservation of mass and the internal consistency of the calculations.\n\nFinally, the problem requires that all three quantities be rounded to two significant figures.\n1.  Absorbed dose: $D_{abs} = 0.49$ mg. This value already has two significant figures (the digits $4$ and $9$).\n2.  Amount retained in bone: $M_{bone} = 0.294$ mg. To round to two significant figures, we examine the third significant digit ($4$). Since $4 < 5$, we round down (i.e., truncate). The result is $0.29$ mg.\n3.  Amount renally excreted: $M_{renal} = 0.196$ mg. To round to two significant figures, we examine the third significant digit ($6$). Since $6 \\ge 5$, we round up the preceding digit. The result is $0.20$ mg.\n\nThe three requested quantities, in order and rounded to two significant figures, are $0.49$ mg, $0.29$ mg, and $0.20$ mg.",
            "answer": "$$\\boxed{\\begin{pmatrix} 0.49 & 0.29 & 0.20 \\end{pmatrix}}$$"
        },
        {
            "introduction": "By combining our knowledge of a drug's mechanism and its pharmacokinetics, we can begin to predict its effects on the patient. This final practice problem integrates pharmacodynamics with physiology to model a critical clinical scenario: the risk of hypocalcemia following a bisphosphonate infusion in a susceptible patient. By building a mass-balance model of calcium homeostasis, you will not only calculate the probability of this adverse event but also determine a corrective supplementation strategy, bridging the gap from pharmacological theory to clinical problem-solving. ",
            "id": "4945651",
            "problem": "A $70$ kg adult with vitamin D deficiency is scheduled to receive a first infusion of zoledronic acid. Consider the ionized calcium compartment to be the extracellular fluid (ECF), with volume $V$ proportional to body weight. Use the following scientifically grounded assumptions to model the first $24$ hours after infusion and to quantify the risk of hypocalcemia and the supplementation needed to maintain ionized calcium concentration $[\\mathrm{Ca}^{2+}]$:\n\n- The ECF volume is $V = 0.2 \\,\\mathrm{L\\,kg^{-1}} \\times 70\\,\\mathrm{kg}$.\n- Baseline ionized calcium concentration is $C_{0} = 1.20 \\,\\mathrm{mmol\\,L^{-1}}$.\n- Define the hypocalcemia threshold as $C_{\\mathrm{h}} = 1.05 \\,\\mathrm{mmol\\,L^{-1}}$.\n- Baseline dietary calcium intake is $500 \\,\\mathrm{mg\\,day^{-1}}$, which equals $I = \\frac{500}{40} \\,\\mathrm{mmol\\,day^{-1}}$ of elemental calcium.\n- In vitamin D deficiency, the baseline fractional intestinal calcium absorption is $f_{0} = 0.10$. Over the first $24$ hours, parathyroid hormone (PTH)–mediated compensation can increase fractional absorption only modestly to $f_{1} = 0.12$.\n- The baseline osteoclastic bone resorption calcium flux into the ECF is $R_{b} = 5.0 \\,\\mathrm{mmol\\,day^{-1}}$. Osteoblastic bone formation is assumed unchanged over the first $24$ hours.\n- Zoledronic acid acutely suppresses the resorptive flux by a fraction $s$. Model $s$ as a normally distributed random variable $s \\sim \\mathcal{N}(\\mu, \\sigma^{2})$ with $\\mu = 0.60$ and $\\sigma = 0.10$. Ignore truncation at the $[0,1]$ bounds for the purpose of the probability calculation.\n- Over the first $24$ hours, renal compensation is neglected for simplicity. The net calcium balance change affecting the ECF is the decrease in bone-derived influx minus the small increase in gut absorption due to the change from $f_{0}$ to $f_{1}$ at intake $I$.\n- Treat the $24$-hour change in ECF ionized calcium concentration, $\\Delta C_{24}$, as the net flux change divided by $V$, applied over $1$ day.\n\nTasks:\n1) Using a mass-balance argument, compute the probability (expressed as a decimal, not a percentage) that the $24$-hour ionized calcium concentration $C_{24}$ will fall below $C_{\\mathrm{h}}$ given the variability in $s$. Round your probability to three significant figures.\n2) Compute the daily elemental calcium supplementation $S$ that should be added to the $500 \\,\\mathrm{mg\\,day^{-1}}$ baseline intake so that, for the expected suppression $s = \\mu$, the $24$-hour ionized calcium concentration remains at $C_{0}$ (that is, the expected $\\Delta C_{24} = 0$). Assume that the supplement is absorbed with the same fractional absorption $f_{1}$. Express $S$ in milligrams of elemental calcium per day and round to three significant figures.\n\nProvide your final numerical results with the specified rounding. For $S$, express the final amount in $\\mathrm{mg\\,day^{-1}}$ of elemental calcium. Do not use a percentage sign anywhere; express probabilities as decimals.",
            "solution": "The problem is first validated to ensure it is scientifically grounded, self-contained, and well-posed.\n\n**Step 1: Extract Givens**\n- Body weight: $70 \\,\\mathrm{kg}$\n- Extracellular fluid (ECF) volume: $V = 0.2 \\,\\mathrm{L\\,kg^{-1}} \\times 70\\,\\mathrm{kg}$\n- Baseline ionized calcium concentration: $C_{0} = 1.20 \\,\\mathrm{mmol\\,L^{-1}}$\n- Hypocalcemia threshold concentration: $C_{\\mathrm{h}} = 1.05 \\,\\mathrm{mmol\\,L^{-1}}$\n- Baseline dietary calcium intake: $500 \\,\\mathrm{mg\\,day^{-1}}$\n- Molar mass of elemental calcium implied: $40 \\,\\mathrm{mg\\,mmol^{-1}}$ (from $I = \\frac{500}{40} \\,\\mathrm{mmol\\,day^{-1}}$)\n- Baseline elemental calcium intake: $I = \\frac{500}{40} \\,\\mathrm{mmol\\,day^{-1}}$\n- Baseline fractional intestinal absorption: $f_{0} = 0.10$\n- Post-treatment fractional intestinal absorption: $f_{1} = 0.12$\n- Baseline osteoclastic bone resorption flux: $R_{b} = 5.0 \\,\\mathrm{mmol\\,day^{-1}}$\n- Fractional suppression of resorption flux: $s \\sim \\mathcal{N}(\\mu, \\sigma^{2})$ with $\\mu = 0.60$ and $\\sigma = 0.10$.\n- Time period: $24$ hours ($1$ day).\n- Modeling assumptions: Osteoblastic bone formation is unchanged. Renal compensation is neglected. Change in ECF concentration $\\Delta C_{24}$ is the net flux change over $1$ day divided by $V$.\n\n**Step 2: Validate Using Extracted Givens**\nThe problem is scientifically grounded, modeling a realistic clinical scenario of bisphosphonate-induced hypocalcemia in a vitamin-D deficient patient. The physiological parameters (ECF volume, calcium levels, intake, resorption rates) and drug effects are within plausible ranges. The problem is well-posed, providing all necessary information and assumptions (e.g., neglecting renal compensation, unchanged bone formation) to solve for the requested quantities. The language is objective and the tasks are clearly defined. The problem is therefore deemed valid.\n\n**Step 3: Verdict and Action**\nThe problem is valid. A full solution is warranted.\n\n**Solution**\n\nFirst, we calculate the constant parameters.\nThe ECF volume $V$ is:\n$$V = 0.2 \\,\\mathrm{L\\,kg^{-1}} \\times 70\\,\\mathrm{kg} = 14 \\,\\mathrm{L}$$\nThe baseline daily elemental calcium intake $I$ is:\n$$I = \\frac{500 \\,\\mathrm{mg\\,day^{-1}}}{40 \\,\\mathrm{mg\\,mmol^{-1}}} = 12.5 \\,\\mathrm{mmol\\,day^{-1}}$$\n\n**Part 1: Probability of Hypocalcemia**\n\nHypocalcemia is defined as the ionized calcium concentration after $24$ hours, $C_{24}$, falling below the threshold $C_{\\mathrm{h}}$.\n$$C_{24} < C_{\\mathrm{h}}$$\nThe concentration at $24$ hours is the baseline concentration plus the change over $24$ hours, $C_{24} = C_{0} + \\Delta C_{24}$. The condition for hypocalcemia is:\n$$C_{0} + \\Delta C_{24} < C_{\\mathrm{h}}$$\n$$ \\Delta C_{24} < C_{\\mathrm{h}} - C_{0} = 1.05 \\,\\mathrm{mmol\\,L^{-1}} - 1.20 \\,\\mathrm{mmol\\,L^{-1}} = -0.15 \\,\\mathrm{mmol\\,L^{-1}}$$\nThe change in concentration, $\\Delta C_{24}$, is the net change in the molar amount of calcium in the ECF, $\\Delta N_{24}$, divided by the ECF volume $V$.\n$$\\Delta C_{24} = \\frac{\\Delta N_{24}}{V}$$\nThe net change $\\Delta N_{24}$ over the $1$-day period is the sum of the changes in influxes. The problem specifies that these are from bone resorption and intestinal absorption.\nThe change in influx from intestinal absorption is the new absorbed amount minus the old absorbed amount:\n$$\\Delta J_{\\mathrm{abs}} = f_{1}I - f_{0}I = (f_{1} - f_{0})I$$\nThe change in influx from bone resorption is the new resorption rate minus the old rate. Zoledronic acid suppresses the baseline resorption $R_{b}$ by a fraction $s$, so the new rate is $(1-s)R_{b}$. The change is:\n$$\\Delta J_{\\mathrm{resorp}} = (1-s)R_{b} - R_{b} = -sR_{b}$$\nThe total change in the amount of calcium in the ECF over $1$ day is the sum of these flux changes multiplied by the time period $T=1\\,\\mathrm{day}$:\n$$\\Delta N_{24} = (\\Delta J_{\\mathrm{abs}} + \\Delta J_{\\mathrm{resorp}}) \\times T = ((f_{1} - f_{0})I - sR_{b}) \\times 1\\,\\mathrm{day}$$\nSubstituting the numerical values (in units of mmol):\n$$\\Delta N_{24} = ((0.12 - 0.10) \\times 12.5 - s \\times 5.0) = 0.25 - 5.0s$$\nThe condition for hypocalcemia, $\\Delta C_{24} < -0.15 \\,\\mathrm{mmol\\,L^{-1}}$, becomes:\n$$\\frac{\\Delta N_{24}}{V} < -0.15 \\,\\mathrm{mmol\\,L^{-1}}$$\n$$\\frac{0.25 - 5.0s}{14} < -0.15$$\nWe solve this inequality for the random variable $s$:\n$$0.25 - 5.0s < -0.15 \\times 14$$\n$$0.25 - 5.0s < -2.1$$\n$$-5.0s < -2.1 - 0.25$$\n$$-5.0s < -2.35$$\nMultiplying by $-1$ reverses the inequality sign:\n$$5.0s > 2.35$$\n$$s > \\frac{2.35}{5.0} = 0.47$$\nWe need to find the probability $P(s > 0.47)$. The suppression fraction $s$ is normally distributed: $s \\sim \\mathcal{N}(\\mu=0.60, \\sigma=0.10)$. We standardize this variable by defining $Z = \\frac{s - \\mu}{\\sigma}$, where $Z \\sim \\mathcal{N}(0, 1)$.\n$$P(s > 0.47) = P\\left(\\frac{s - \\mu}{\\sigma} > \\frac{0.47 - \\mu}{\\sigma}\\right)$$\n$$P\\left(Z > \\frac{0.47 - 0.60}{0.10}\\right) = P\\left(Z > \\frac{-0.13}{0.10}\\right) = P(Z > -1.3)$$\nDue to the symmetry of the standard normal distribution, $P(Z > -z) = P(Z < z)$. Let $\\Phi(z)$ be the cumulative distribution function for the standard normal distribution.\n$$P(Z > -1.3) = P(Z < 1.3) = \\Phi(1.3)$$\nUsing a standard normal distribution table or calculator, $\\Phi(1.3) \\approx 0.903199$.\nRounding to three significant figures, the probability is $0.903$.\n\n**Part 2: Calcium Supplementation**\n\nWe need to find the daily elemental calcium supplementation $S$ (in mg) such that the calcium concentration remains at $C_{0}$, meaning $\\Delta C_{24} = 0$. This requires the net change in ECF calcium amount, $\\Delta N_{24}$, to be zero. This calculation is performed for the expected suppression, $s = \\mu = 0.60$.\nLet $I_{S}$ be the supplementation in $\\mathrm{mmol\\,day^{-1}}$. The total daily intake becomes $I + I_{S}$. This total intake is absorbed with fractional absorption $f_1$. The influx from the supplement is $f_1 I_S$.\nThe condition $\\Delta N_{24} = 0$ is based on the total change from the initial baseline state.\nThe change is the sum of the change without the supplement and the added influx from the supplement:\n$$\\Delta N_{24} = \\left((f_{1} - f_{0})I - sR_{b}\\right) + f_{1}I_{S} = 0$$\nWe use $s = \\mu = 0.60$ and solve for $I_{S}$:\n$$f_{1}I_{S} = \\mu R_{b} - (f_{1} - f_{0})I$$\n$$I_{S} = \\frac{\\mu R_{b} - (f_{1} - f_{0})I}{f_{1}}$$\nSubstituting the values:\n$$I_{S} = \\frac{(0.60 \\times 5.0) - ((0.12 - 0.10) \\times 12.5)}{0.12}$$\n$$I_{S} = \\frac{3.0 - (0.02 \\times 12.5)}{0.12} = \\frac{3.0 - 0.25}{0.12} = \\frac{2.75}{0.12}$$\n$$I_{S} \\approx 22.9166... \\,\\mathrm{mmol\\,day^{-1}}$$\nTo convert this molar amount to a mass $S$ in $\\mathrm{mg\\,day^{-1}}$, we use the molar mass of calcium, $40 \\,\\mathrm{mg\\,mmol^{-1}}$:\n$$S = I_{S} \\times 40 \\,\\mathrm{mg\\,mmol^{-1}} = \\frac{2.75}{0.12} \\times 40 \\approx 916.666... \\,\\mathrm{mg\\,day^{-1}}$$\nRounding to three significant figures, the required supplementation is $S = 917 \\,\\mathrm{mg\\,day^{-1}}$.",
            "answer": "$$\\boxed{\\begin{pmatrix} 0.903 & 917 \\end{pmatrix}}$$"
        }
    ]
}